CD8A and neoplasm: For instance, CD8+ T cell-derived EVs exert immuno-activating properties and are being used in several research works with the intent to shrink tumor growth, whereas Treg cell-derived EV administration is emerging as a promising strategy for transplantation tolerance because of the immunomodulatory effects [130,131].